Search Results
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
IgA Nephropathy Market IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report
More news about: DelveInsight Business Research, LLP
Oct 01, 2025, 07:11 ET RapidIdentity: Leading the Charge in Identity Management for Ohio's Higher Education
that facilitates streamlined and secure access, effectively addressing their evolving Identity and Access Management (IAM) and Identity Governance (IGA) challenges. With RapidIdentity, these institutions now have easy access to a market-leading platform designed specifically to meet the ever-evolving
More news about: Identity Automation, a Jamf company
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
compared to 16% of patients receiving placebo (p<0.001) achieved high levels of skin clearance (IGA score of 0/1). Nearly 40% of pediatric patients receiving TREMFYA® achieved complete clearance (IGA 0) at Week 16 compared to 4% on placebo (p<0.01).6 Approval
More news about: Johnson & Johnson
Sep 29, 2025, 07:00 ET Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations.
you are not sure. You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, and have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.
More news about: Kedrion Biopharma
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
travere.com. About IgA Nephropathy IgA Nephropathy, also called Berger's disease, is a rare progressive kidney disease characterized by the abnormal buildup of immunoglobulin A (IgA), an antibody that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of
More news about: Vifor International AG (CSL Vifor)
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
travere.com. About IgA Nephropathy IgA Nephropathy, also called Berger's disease, is a rare progressive kidney disease characterized by the abnormal buildup of immunoglobulin A (IgA), an antibody that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of
More news about: Vifor International AG (CSL Vifor)
Sep 24, 2025, 09:00 ET ONE IDENTITY NAMES SOFTWARE INDUSTRY LEADER PRAERIT GARG AS CEO
Identity Fabric, a holistic approach to identity and access management (IAM). By unifying IAM tools, including identity governance and administration (IGA), access management (AM), privileged access management (PAM), and Active Directory management (AD Mgmt), it ensures optimal functionality and efficiency.
More news about: One Identity
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
activity and B-cell maturation, providing a synergistic approach to treating autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, IgA nephropathy and Sjögren's syndrome. LBL-047 is further optimized with glycosylation modifications to enhance antibody-dependent cellular cytotoxicity
More news about: Leads Biolabs
Sep 17, 2025, 19:30 ET Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Primary endpoints included the percent treatment success, defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12, the percent reductions from baseline to week 12 in total lesion count (TLC), and the
More news about: Ascletis Pharma Inc.
Sep 17, 2025, 10:30 ET Agentic ITSM platform Atomicwork announces strategic investment from Okta Ventures
Through this partnership, Atomicwork and Okta will build integrations that embed identity, access intelligence, and IGA into everyday service delivery. For example, when an employee can't access Workday, they simply message Atom (Atomicwork's Universal AI Agent)
More news about: Atomicwork Inc
Sep 17, 2025, 08:00 ET Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.b. Drs. Soung and Stein Gold are
More news about: Johnson & Johnson
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
expected to commence in January 2026. BW-40202 is also being evaluated in a Phase I study as a potential treatment for IgA Nephropathy (IgAN). The Phase I/IIa IND approval was obtained from the NMPA in China in June
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 14, 2025, 19:45 ET 耐賦康®7項最新真實世界數據將亮相第18屆IgA腎病國際研討會
李貴森，四川省醫學科學院•四川省人民醫院 04 編號：P-63英文標題：First real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis中文標題：首個耐賦康®對兒童IgA腎病或IgA血管炎腎炎的療效的真實世界證據內容概述：旨在評估耐賦康®對兒童IgA腎病或IgA血
More news about: 雲頂新耀
Sep 11, 2025, 08:03 ET Omada simplifies and accelerates IGA deployment while lowering total cost of ownership
Omada Identity Cloud, the company's IGA-as-a-service platform, and on-premises or cloud-hosted target systems. This can be done without requiring changes to firewall configurations, offering agility and Zero Trust alignment, ideal for modern, distributed IGA deployments.
More news about: Omada
Sep 09, 2025, 09:00 ET GAMING INDUSTRY'S TOP CEOs BILL HORNBUCKLE, PETER JACKSON & JASON ROBINS TO KEYNOTE G2E 2025
6 at 4 p.m.Doors open at 3:30 p.m. Indian Gaming Association (IGA) Chairman Ernie Stevens Jr. will open the main stage by underscoring the central contributions of tribal operators to
More news about: American Gaming Association
Sep 09, 2025, 02:00 ET Honda Prize 2025 Awarded to Dr. Kenichi Iga of Japan
systems for autonomous vehicles. When Dr. Iga first proposed VCSEL, his concept was met with skepticism from both academia and industry due to concerns about its feasibility. However, through persistent research and continuous advocacy, Dr. Iga and his team gradually established global recognition
More news about: Honda Foundation
Sep 04, 2025, 17:18 ET CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial
The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints 59% of patients achieved IGA treatment success 71% of patients experienced ≥4-point improvement in worst itch
More news about: CAGE Bio Inc.
Sep 04, 2025, 08:05 ET Lactiga Wins NIH Backing for First-in-Class Breastmilk-Derived Antibody in Inflammatory Bowel Disease
the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases, to advance the development of its secretory IgA (sIgA) antibody for inflammatory bowel disease (IBD).
More news about: Lactiga US, Inc.
Sep 03, 2025, 08:00 ET SPHERE Advances Identity Intelligence with SPHEREboard 6.11 Launch and Strategic Advisory Board
credential management, RBAC configuration, and installation improvements—all designed to streamline enterprise deployments. "Even with mature IGA, AM and PAM solutions, many organizations struggle to achieve full visibility ("single pane of glass") in a reasonable timeline and at sustainable cost.
More news about: SPHERE
Aug 28, 2025, 19:45 ET 雲頂新耀發布2025年中期業績及業務進展
2025年5月，耐賦康®被納入《中國成人IgA腎病及IgA血管炎臨床實踐指南（預審版本）》，推薦對有疾病進展風險的IgA腎病患者進行9個月的布地奈德腸溶膠囊對因治療，不受蛋白尿水平的限制，以降低致病性IgA（Gd-IgA1）。指南建議對於蛋白尿≥0.5
More news about: 雲頂新耀
Aug 28, 2025, 19:44 ET Everest Medicines Announces Interim Results for First Half of 2025
enteric-coated capsules in IgA nephropathy" and "Predictive Value of Gd-IgA1, Poly-IgA in the Treatment of IgA Nephropathy with Targeted Release Formulation-Budesonide" by Prof. Lv Jicheng (Department of Nephrology, Peking University First Hospital), "Efficacy and safety of TRF-budesonide in IgA nephropathy treatment:
More news about: Everest Medicines
Aug 26, 2025, 09:09 ET AliveDx registriert MosaiQ®, sein Instrument für Multiplex-Tests auf Autoimmunerkrankungen, Allergien und darüber hinaus, als ein von der US-amerikanischen Food and Drug Administration (FDA) zugelassenes Medizinprodukt der Klasse II.
Sjögren, SSc) auf einem Microarray.AiPlex ® CD* - Zöliakie-Panel (5 Marker) mit einer Kombination von IgA- und IgG-Markern auf einem Microarray.AiPlex ® VAS* - Vaskulitis Panel (3 Marker), wichtige Autoantikörpermarker
More news about: AliveDx Suisse SA
Aug 26, 2025, 09:05 ET AliveDx enregistre MosaiQ®, son instrument destiné aux tests multiplex de maladies auto-immunes, d'allergies et autres pathologies, comme dispositif de classe II exempté de notification préalable à la mise en marché auprès de la Food and Drug Administration (FDA) des États-Unis
seule biopuce.AiPlex ® CD* – Panel pour la maladie cœliaque (5 marqueurs) combinant les marqueurs IgA et IgG sur une seule biopuce.AiPlex ® VAS* – Panel pour la vascularite (3 marqueurs), marqueurs auto-immuns
More news about: AliveDx Suisse SA
Aug 26, 2025, 09:00 ET AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
SLE, Sjögren's, SSc) on one microarray.AiPlex® CD* – Celiac disease panel (5 markers) combining IgA and IgG markers on one microarray.AiPlex® VAS* – Vasculitis panel (3 markers), key autoantibody markers
More news about: AliveDx Suisse SA
Aug 26, 2025, 09:00 ET AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
SLE, Sjögren's, SSc) on one microarray.AiPlex® CD* – Celiac disease panel (5 markers) combining IgA and IgG markers on one microarray.AiPlex® VAS* – Vasculitis panel (3 markers), key autoantibody markers
More news about: AliveDx Suisse SA